Enanta Pharmaceuticals (ENTA) Income from Continuing Operations (2012 - 2026)

Enanta Pharmaceuticals has reported Income from Continuing Operations for 15 years, with the latest figure at 13091000.0 in Q1 2026.

• For the quarter ending Q1 2026, Income from Continuing Operations rose 42.19% year-over-year to 13091000.0; the trailing twelve-month figure through Mar 2026 stood at 61984000.0 (up 35.58% YoY), and the FY2025 full-year result was 81889000.0, up 29.32% from the prior year.
• Income from Continuing Operations for Q1 2026 stood at 13091000.0, down from 11938000.0 in the prior quarter.
• The five-year high for Income from Continuing Operations was 11938000.0 in Q4 2025, with the low at 39065000.0 in Q2 2023.
• Historically, Income from Continuing Operations has averaged 26366235.29 across 5 years, with a median of 28107000.0 in 2023.
• The largest YoY upside for Income from Continuing Operations was 67.83% in 2022 against a maximum downside of 31.95% in 2022.
• Enanta Pharmaceuticals' Income from Continuing Operations stood at 28986000.0 in 2022, then decreased by 15.25% to 33407000.0 in 2023, then surged by 33.28% to 22290000.0 in 2024, then surged by 46.44% to 11938000.0 in 2025, then slipped by 9.66% to 13091000.0 in 2026.
• The last three Income from Continuing Operations figures came in at 13091000.0 (Q1 2026), 11938000.0 (Q4 2025), and 18700000.0 (Q3 2025), per Business Quant data.